Argus Pharmaceuticals of Houston has appointed David M.Leech president and chief executive, following the retirementof George Goldenberg. Leech was president and CEO of HoustonBiotechnology Inc. Argus is developing potential treatments forAIDS, cancer and serious fungal infections.
Enzymatics of Horsham, Pa., has named Donald E. Kuhlaexecutive vice president and chief operating officer andWilliam R. Patterson vice president of operations. Kuhla waspresident and chief operating officer of Hybridon Inc.Patterson was senior vice president of operations for VentrexLaboratories. Enzymatics develops rapid diagnostic products totest alcohol and cholesterol levels and other substances.
Escagenetics Corp. of San Carlos, Calif., has named William R.Sharp vice president of pharmaceuticals. Sharp is a founder ofDNA Plant Technology Corp. and adjunct professor at Ohio Stateand Rutgers universities. Escagenetics (AMEX:ESN) developsplant-derived products for the pharmaceutical and foodprocessing industries.
Interneuron Pharmaceuticals Inc. of Lexington, Mass., hasnamed Jeffrey L. Dow vice president and general counsel andWilliam B. Boni director of corporate communications. Dow wasvice president for legal and regulatory affairs at KendallHealthcare Products Co. Boni was deputy director at Hill andKnowlton Inc. Interneuron (NASDAQ:IPIC) is focused onpharmaceutical products for neurological and behavioraldisorders.
Gilead Sciences Inc. of Foster City, Calif., has named Dr. Lawrence L.-K Leung director of vascular biology and medicine. Leung hadbeen an associate professor at the Stanford University MedicalSchool. Gilead (NASDAQ:GILD) is developing pharmaceuticalsbased on nucleotides.
Nobel laureate Dr. Jean Dausset has been elected to the board ofSangStat Medical Corp. of Menlo Park, Calif. Dausset, whoreceived the Nobel prize in physiology and medicine in 1980, isthe founder and president of the Centre d' Etude duPolymorphisme Humain of Paris. Privately held SangStat isdeveloping therapeutic and monitoring products for the organtransplantation business.
S.R. Blair, chairman emeritus of Nova Corp. of Calgary, has beennamed to the board of Biomira Inc. of Edmonton, Alberta.Biomira (NASDAQ:BIOMF) is focused on cancer diagnostic andtherapeutic products.
Paul W. Sheppard has been named scientific developmentdirector of Affiniti Research Products Ltd., a neuroscienceresearch products company based in Derbyshire, England.Sheppard was technology manager for the strategic planningand business development group of ICI plc's bioproducts andfine chemicals business.
(c) 1997 American Health Consultants. All rights reserved.